Array BioPharma has been developing products for over 25 years. In late 2017, they made the decision to commercialize their first product, a combination therapy treating metastatic melanoma with a BRAF mutation. Array brought on CultHealth as their patient AOR to help prepare for the launch, which was 6 months out. Having previously worked with CultHealth, our client knew that we would be able to get up to speed in the category/science in record time, help establish MLR standards, and accomplish our goal of being able to help patients successfully onboard their therapy. We helped patients navigate a complex dosing regimen and remain adherent to their medication, all while seeing prescription rates increase by 50% above the client’s goal. We were able to do this on time and on budget and went further than traditional agency roles to help establish patient and MLR best practices across the company.